序号股票简称PE(TTM)PE(静)市净率总市值(元)13海尔生物29.7027.482.26100.76亿行业平均 52.3447.744.60110.17亿行业中值36.9936.882.5451.28亿1九安医疗11.0211.150.87186.01亿2英科医疗 12.1013.041.08191.13亿3新华医疗14.8113.731.2194.95亿4振德医疗15.4114.530.9855.95亿5山东药玻 15.8315.881.82149.71亿6奥美医疗15.8415.531.6357.25亿7康德莱16.4816.491.3735.51亿8奥泰生物 16.9717.891.3754.11亿9九强生物17.0915.892.0984.66亿10维力医疗17.6618.352.0740.27亿11安图生物 19.1918.322.46218.80亿12三鑫医疗19.3319.343.1843.99亿 7月18日，海尔生物今日收盘31.69元，上涨1.02%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到29.70倍，创43天以来新低，总市值100.76亿元。 从行业市盈率排名来 ...

6月18日，海尔生物今日收盘30.28元，下跌1.62%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到28.38倍，总市值96.28亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.10倍，行业中值36.43倍，海尔生物排 名第65位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13海尔生物28.3826.262.1696.28亿行业平均 49.1047.114.54105.10亿行业中值36.4336.872.3948.92亿1英科医疗9.5610.310.85151.03亿2九安医疗 10.1210.230.80170.79亿3新华医疗14.2213.181.1691.18亿4振德医疗14.6413.800.9353.16亿5康德莱 14.7414.751.2231.75亿6奥美医疗14.8614.571.5353.70亿7山东药玻15.7315.781.81148.78亿8九强生物 15.7414.641.9377.95亿9维力医疗15.7716.391.8535.96亿10奥泰生物16.0716.951.3051.26亿11安杰思 17.3817.582. ...

Core Viewpoint - Haier Biomedical's stock closed at 30.92 yuan, down 1.34%, with a rolling PE ratio of 28.98 times, and a total market value of 9.831 billion yuan [1] Company Overview - Qingdao Haier Biomedical Co., Ltd. focuses on providing optimal user experiences for life science users, including pharmaceutical companies, research institutions, and healthcare users, forming two main business segments: life sciences and medical innovation [2] - The company offers comprehensive digital solutions represented by smart laboratories, digital hospitals, and smart public health, with key products including low-temperature storage boxes, automated biological sample storage, and various automated medication products [2] Financial Performance - In Q1 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, a year-on-year decrease of 19.88%, with a gross profit margin of 48.35% [3] - The company's PE ratio is significantly lower than the industry average of 48.92 times and the industry median of 35.68 times, ranking 66th in the industry [3]

Group 1 - Midea Group has established Midea Medical to expand its ToB business, focusing on technology-driven solutions in the global healthcare industry [1][3] - Midea's ToB business revenue exceeded 100 billion yuan last year, with significant growth in sectors such as new energy and industrial technology, smart building technology, and robotics [1][2] - Midea Medical aims to enhance its brand influence and participate in medical transformation by leveraging advanced technologies and collaborating with institutions like Tsinghua University [1][4] Group 2 - Midea Medical focuses on two main areas: clinical medical technology and hospital construction and operation, providing diagnostic services and optimizing operational efficiency [2][3] - The company has partnered with over 100,000 hospitals globally, offering diagnostic advice to more than 7,000 hospitals in China [2] - Midea Medical's collaboration with various research institutes aims to strengthen its R&D capabilities and develop high-end medical products with independent intellectual property rights [3][4] Group 3 - Recent product launches by Midea Medical include advanced MRI and CT systems, showcasing the application of AI technology in clinical settings [4] - The entry of home appliance companies into the medical sector is a growing trend, with companies like Gree and Haier also expanding into healthcare [4][5] - The shift towards the healthcare sector is driven by factors such as aging populations, increased health awareness, and the need for diversification in the home appliance industry [5][6]

Group 1 - The core viewpoint of the news is that Haier Biomedical's stock performance and financial metrics indicate a relatively low valuation compared to the industry average, despite a decline in net profit [1][3]. - As of April 28, Haier Biomedical's closing stock price was 31.02 yuan, down 2.36%, with a rolling PE ratio of 26.90 times and a total market capitalization of 9.863 billion yuan [1]. - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Haier Biomedical at the 64th position in the industry ranking [1][3]. Group 2 - Haier Biomedical focuses on providing comprehensive digital solutions for life sciences and healthcare, targeting pharmaceutical companies, research institutions, and various healthcare users [2]. - The company's main products include low-temperature storage boxes, automated biological sample storage systems, and various laboratory automation equipment [2]. - In 2022, Haier Biomedical received several prestigious awards and certifications, enhancing its reputation in the life sciences and medical innovation sectors [2]. Group 3 - For the fiscal year 2024, Haier Biomedical reported a revenue of 2.284 billion yuan, a slight increase of 0.13% year-on-year, while net profit decreased by 9.71% to 367 million yuan [3]. - The company's gross profit margin stands at 47.99% [3]. - The stock's PE ratio is significantly lower than the industry average, indicating potential undervaluation [3].

Group 1 - TÜV Rheinland awarded Haier Biomedical the first EU MDR certificate for medical low-temperature storage devices, indicating compliance with international standards for safety and effectiveness [1] - The certification allows Haier Biomedical's products to enter the EU market and accelerates registration processes in Southeast Asia, the Middle East, and Africa [1] - The demand for medical low-temperature storage devices is increasing due to advancements in life sciences and biotechnology, driving market growth [1] Group 2 - The acquisition of the EU MDR certificate reflects Haier Biomedical's international innovation strategy and commitment to product quality and compliance [2] - As of the end of 2024, Haier Biomedical has obtained over 400 overseas certifications, including more than 200 EU CE certifications and 70 US FDA certifications [2] - The company emphasizes self-innovation and high standards to enhance its international market presence [2]

当前，AI与医疗健康的融合已从技术探索迈向规模化应用，推动行业进入数智化转型新阶段。4月8日-11日， 在 第91届中国国际医疗器械(春季)博览会 (以下简称"CMEF") 上，盈康一生旗下 海尔生物医疗 以"Ai在海 尔，因Ai盈康 "为主题，携多个"AI+智慧场景"和15大明星产品重磅亮相。 从AI+智慧样本库、AI+智慧科研，到AI+智慧用药、AI+智慧疫苗接种、AI+智慧血液管理，海尔生物医疗以新 科技、新场景、新生态，不仅为行业带来一场生命科学与医疗创新+AI的生态成果盛宴，也为产业重构带来了 未来想象空间。 # 逐"绿"向"智"，构建生命科学研究新范式 在可持续发展与智能化转型浪潮下，绿色科技与AI技术正重构生命科学产业范式，加速推进全链条数智化进 程。此次CMEF上，海尔生物医疗立足 样本高质量保藏管理和医院临床干细胞研究 ，为高校、科研机构、医 院、药企等用户带来了 一站式样本库全生命周期解决方案、可按需定制的智慧实验室场景解决方案 等，助力 生命科学研究和前沿医学进步。 在AI+智慧样本库展区，海尔生物医疗立足高质量样本库建设需求，带来了 一站式样本库全生命周期解决方案 和4大首发新品。 基 ...

深耕生物医疗领域，厚积薄发展实力 导读： 2025年4月8日，第91届CMEF开幕，美的医疗携多款新品亮相，以 "全维智变" 破局。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 2 0 2 5年4月8日，第9 1届中国国际医疗器械（春季）博览会（CMEF）在上海国家会展中心拉开 帷幕。这场盛会汇聚了全球医疗行业的前沿科技与创新力量，而美的医疗携多款重磅新品亮 相， 以"全维智变"破局医疗困局 ，为国内 AI赋能医疗提供全新视角与解题思路 。 美的与生物医疗领域的缘分，早在2 0 11年便已结下。彼时，美的组织团队开展相关技术和产品 的先研工作，悄然开启了生命科学领域的探索之旅。2 0 2 1年，美的生物医疗正式成立，标志着 美的在该领域的布局进一步深化。 依托美的集团三十余年深厚的制冷技术积累，美的生物医疗在低温存储设备生物安全领域不断 发力，推出智慧生物样本库场景化解决方案，荣获第三届"金如意奖"临床科研价值奖；专注低 温安全存储技术研发， 核心产品- 8 6℃睿云超低温冰箱 ，实现样本的安全存储和高效管理；从 方案设计、基础建设到 ...